
Phase 3 Trial Finds Oral Empagliflozin Provided Safe Glycemic Control in Children with Type 2 Diabetes
Joslin Diabetes Center researchers completed a phase 3 clinical trial of two different classes of oral agents for the treatment of type 2 diabetes in young people aged 10-17 years. Read about their findings.
Read more on Phase 3 Trial Finds Oral Empagliflozin Provided Safe Glycemic Control in Children with Type 2 Diabetes